See which stocks both gurus owned in the first quarter.
Young biotech Pharmacyclics is developing a treatment for lymphoma and myeloma.
Growth in the segment has stunted over the past few years, prompting the new CEO to look at acquisitions.
The cosmetics company needs more time to think about the latest bid.
A jittery Europe, a slowing China, and a weak US recovery means rock-solid income is a great choice for investors looking to ride out the storm.
Mergers and acquisitions activity is heating up among big pharma and biotechs.
These stocks have yet to claw their way back to their perches before the financial crisis, but they're finally showing signs of life.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The retailer labels the character's fake memoir as non-fiction. This comes weeks after it categorized the the Bible as fiction.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Preteens, rejoice. The grown-ups have a compelling reason to consider getting you a tablet this year. Adults, listen up.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.